Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We used wholegenome sequencing to perform an unbiased comprehensive screen to discover the somatic mutations in a sample from an individual with sAML and genotyped the loci containing these mutations in the matched MDS sample. Here we show that a missense mutation affecting the serine at codon 34 (Ser34) in U2AF1 was recurrently present in 13 out of 150 (8.7%) subjects with de novo MDS, and we found suggestive evidence of an increased risk of progression to sAML associated with this mutation. U2AF1 is a U2 auxiliary factor protein that recognizes the AG splice acceptor dinucleotide at the 3′ end of introns, and the alterations in U2AF1 are located in highly conserved zinc fingers of this protein 1,2 . Mutant U2AF1 promotes enhanced splicing and exon skipping in reporter assays in vitro. This previously unidentified, recurrent mutation in U2AF1 implicates altered pre-mRNA splicing as a potential mechanism for MDS pathogenesis.
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We used wholegenome sequencing to perform an unbiased comprehensive screen to discover the somatic mutations in a sample from an individual with sAML and genotyped the loci containing these mutations in the matched MDS sample. Here we show that a missense mutation affecting the serine at codon 34 (Ser34) in U2AF1 was recurrently present in 13 out of 150 (8.7%) subjects with de novo MDS, and we found suggestive evidence of an increased risk of progression to sAML associated with this mutation. U2AF1 is a U2 auxiliary factor protein that recognizes the AG splice acceptor dinucleotide at the 3′ end of introns, and the alterations in U2AF1 are located in highly conserved zinc fingers of this protein 1,2 . Mutant U2AF1 promotes enhanced splicing and exon skipping in reporter assays in vitro. This previously unidentified, recurrent mutation in U2AF1 implicates altered pre-mRNA splicing as a potential mechanism for MDS pathogenesis.
MDS are a heterogenous group of hematopoietic stem cell disorders characterized by dysplastic blood cell formation and peripheral blood cytopenias. Up to 30% of individuals with MDS will progress to highly chemotherapy-resistant sAML. Whole-genome sequencing (WGS) offers an unbiased approach to discover the genetic mutations present in all types of cancer cell genomes and has been used to identify new mutations in the genomes of de novo AML and therapy-related AML [3] [4] [5] [6] [7] . Here we report the results of WGS of an MDS-derived sAML sample and a matched normal (skin) sample. We performed WGS using 100-bp paired-end reads and obtained 39.1× and 38.2× haploid and 99.3% and 98.9% diploid coverage of the sAML and normal samples, respectively (Supplementary Note and Supplementary Table 1 ). We divided the genome into non-overlapping tiers, as previously described 4 , and validated putative mutations using deep sequencing of captured DNA isolated from the sAML, normal and MDS samples. We validated 507 somatic single nucleotide variants (SNVs) in the sAML sample, including 30 SNVs in protein-coding regions (known as tier 1 mutations) ( Supplementary Tables 2 and 3) . Almost all (505/507) SNVs found in the sAML sample were also detected in the MDS sample, including 30 tier 1 mutations ( Supplementary Fig. 1 and Supplementary Tables 2 and 3) . The same codon in U2AF1 (U2AF35) was mutated in two additional subjects with MDS-derived sAML that we analyzed using WGS (data not shown). This was the only recurrent mutation in these three individuals. To determine the frequency of this mutation in MDS, we sequenced the entire coding region of U2AF1, including nine exons, in diagnostic bone marrow and paired normal (skin) samples from 150 consecutively accrued subjects with de novo MDS (including the index case) and identified 13 individuals (8.7%) with missense mutations affecting the highly conserved serine at amino acid position 34 (Ser34) in U2AF1 (Fig. 1a) . The same nucleotide was mutated in all samples, resulting in either a p.Ser34Phe (n = 11) or p.Ser34Tyr (n = 2) substitution ( Supplementary Table 4 ). One subject with the p.Ser34Phe alteration (unique patient number (UPN) 947519) also had a p.Gln157Arg substitution in U2AF1 that was located in the second zinc finger of the protein (Fig. 1a) . Sequencing of the U2AF1 complementary DNA (cDNA) from this subject revealed that both mutations occurred on the same allele. We detected no other somatic SNVs affecting U2AF1 in these samples. Subsequent analyses focused on the highly recurrent Ser34 alterations.
U2AF1 is the small (35 kDa) subunit of the U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) that is involved in pre-mRNA 5 4 VOLUME 44 | NUMBER 1 | JANUARY 2012 Nature GeNetics l e t t e r s processing (splicing), and U2AF1 forms a heterodimer with the larger subunit U2AF2 (U2AF65) 2 . U2AF1 binds the 3′ AG splice acceptor dinucleotide of the pre-mRNA target intron 2 , and U2AF2 binds the adjacent polypyrimidine tract. We generated PCR amplicons spanning the Ser34 codon using genomic DNA and cDNA templates from unpurified MDS bone marrow cells from 11 subjects with confirmed mutations in U2AF1 and subjected the amplicons to deep sequencing to obtain the mutant allele frequencies. Notably, there was no deletion or uniparental isodisomy that spanned the U2AF1 locus (chromosome 21q22.3) based on SNP arrays and WGS data from the index case. Read counts from the genomic DNA samples (including the sAML sample from the index case and serial MDS samples from two other subjects) showed that the Ser34 mutant allele frequencies were ~40-50%, indicating that the majority of cells in the samples contained a heterozygous mutation, even though the myeloblast counts ranged from 0-21% in the MDS samples ( Fig. 1b) . We obtained similar results from cDNA deep sequencing (~30-50% mutant allele frequency), indicating that both the Ser34 mutant and wild-type alleles were expressed in all the samples tested regardless of myeloblast count (Fig. 1c) . In addition, there was no difference in the total levels of U2AF1 mRNA or the dominant U2AF1 isoform that was expressed in unfractionated MDS bone marrow samples from subjects with and without U2AF1 mutations ( Supplementary Fig. 2a ). Collectively, these results suggest that U2AF1 mutations are an early, initiating genetic event in MDS pathogenesis.
Although eight of the mutant samples had myeloblast counts >5%, subjects with U2AF1 mutations were not restricted to a particular International Prognostic Scoring System (IPSS) category, and these subjects had a median IPSS score of 1 (intermediate-1, INT-1) ( Table 1 and Supplementary Table 5 ). Subjects with a deletion at chromosome 20q or a monosomy 20 karyotype were more likely to also harbor a U2AF1 mutation (P = 0.03), although the number of subjects with U2AF1 mutations and the deletion in chromosome 20q or a monosomy 20 karyotype was small (n = 4) ( Table 1) . We observed no difference in event-free or overall survival between subjects with U2AF1 mutations and those without them ( Fig. 2a,b) . However, the two subjects with U2AF1 mutations with the longest overall survival had previously received hematopoietic stem cell transplants ( Supplementary  Fig. 3 ). Subjects with U2AF1 mutations had an increased probability of progression from MDS to sAML (P = 0.03) ( Fig. 2c) , an observation that will require confirmation in a larger cohort. There was a U2AF1 mutation frequency of 15.2% (7/46) in the subset of subjects with MDS that progressed to sAML compared to a 5.8% frequency (6/104) in the subset that did not. As there was no statistical difference in the myeloblast count or IPSS distribution in subjects with or without U2AF1 mutations (Table 1) , the mutant genotype does not appear to be a surrogate for these well-established predictors of sAML risk.
Splicing involves cleavage of intronic sequences from pre-mRNA followed by the ligation of the remaining exons together to produce a mature mRNA product 8 . Inclusion and exclusion of different exons or utilization of alternative 3′ splice sites during pre-mRNA processing produces multiple protein isoforms that can have different functions within a cell, and alternative splicing can be affected by the amount of U2AF1 in a cell [9] [10] [11] [12] . It is unknown which domain of U2AF1 binds the pre-mRNA. Notably, the Ser34 and Gln157 residues are located within zinc finger domains ( Fig. 1) that may be crucial for RNA binding activity. Indeed, the U2AF1 zinc fingers are structurally similar to the mouse and human ZFP36 family zinc fingers (both CX 8 CX 5 CX 3 H (CCCH) zinc fingers) [13] [14] [15] that bind RNA, and the noncanonical RNA recognition motif (RRM, also known as U2AF homology motif) in U2AF1 only weakly binds RNA 16 .
To examine the effects of the p.Ser34Phe alteration on U2AF1 splicing activity, we used previously described and validated in vitro double-reporter splicing and minigene reporter assays 9, 17 . The double-reporter plasmid constitutively expresses β-galactosidase, and luciferase is expressed only if appropriate splicing removes an upstream intron that contains translational stop codons. Transient coexpression of the double-reporter plasmid pTN24 and U2AF1 l e t t e r s p.Ser34Phe mutant cDNA in cells from the 293T line resulted in a significant increase in splicing (as detected by an increase in the luciferase:β-galactosidase ratio) compared to that resulting from the coexpression of pTN24 and wild-type U2AF1, despite similar total amounts of U2AF1 protein being present in all samples ( Fig. 3a ; P < 0.001). The splicing was similar in cells depleted of endogenous U2AF1 compared to control cells (Fig. 3b , left column), and the increase in splicing observed with the U2AF1 p.Ser34Phe mutant is independent of endogenous U2AF1 amounts ( Fig. 3b , right column; P < 0.001 when U2AF1 p.Ser34Phe mutant samples were compared to their paired vector-alone samples). This suggests that splicing activity in this assay is insensitive to the amount of U2AF1 and that the increased splicing mediated by the mutant protein is attributable to a gain-of-function activity. Next, we examined exon skipping using a minigene reporter plasmid (a human gene fragment containing an upstream and a downstream exon surrounding an intron-flanked exon). Appropriate splicing produces an mRNA with all three exons, whereas exon skipping fuses the upstream and downstream exons only. We measured exon skipping using a GH1 minigene reporter plasmid in cells transiently cotransfected with either wild-type or p.Ser34Phe mutant U2AF1 cDNA. The proportion of transcripts with a skipped exon (lower PCR band in Fig. 3 ) relative to the appropriately spliced GH1 minigene (upper PCR band) is increased in cells expressing the U2AF1 p.Ser34Phe mutant compared to those expressing control or wild-type U2AF1 ( Fig. 3c ; P = 0.01). This increase in exon skipping mediated by mutated U2AF1 remained significant after depletion of endogenous U2AF1 in 293T cells ( Fig. 3c ; P < 0.02). We also observed an increased utilization of alternative 3′ cryptic splice sites in FMR1 in clinical MDS samples with U2AF1 mutations compared to MDS samples without U2AF1 mutations ( Supplementary Fig. 4a ). We confirmed the alternative splicing of FMR1 to be U2AF1-mutation dependent using an FMR1 minigene splicing reporter assay in vitro (Supplementary Fig. 4b) .
Collectively, these results suggest that U2AF1 Ser34 alterations may result in subtle increases in splicing efficiency (Fig. 3a) -or possibly altered isoform expression ( Fig. 3c) -that could induce changes in gene expression. To test whether U2AF1 mutations alter global gene expression, we analyzed mRNA microarray data (Affymetrix U133 Plus 2) obtained from bone marrow CD34 + cells purified from six subjects with MDS with a U2AF1 mutation, nine subjects with MDS without a U2AF1 mutation and four healthy control donors 18 . The U2AF1 mutant samples did not segregate together when using an unsupervised hierarchical clustering algorithm containing all 19 samples; however, the six U2AF1 mutant samples did segregate together when compared to the four control samples only ( Supplementary Fig. 2b ). Next, we identified the genes that were significantly different between the control and mutant samples using a Significance Analysis of Microarrays (SAM) analysis 19 . SAM identified 401 dysregulated probesets (50 upregulated and 351 downregulated) in samples with mutated U2AF1 compared to control samples (false discovery l e t t e r s rate < 0.005) ( Supplementary Fig. 2b and Supplementary Table 6 ). Three of the most enriched functional annotation categories for genes that are downregulated in samples with mutated U2AF1 contained splicing and RRM genes (enrichment scores of 2.5-4.3) ( Supplementary  Fig. 2c and Supplementary Table 6 ). These results suggest that a compensatory downregulation of splicing genes may exist in samples with mutations in U2AF1. These gene categories were not downregulated in subjects with MDS with wild-type U2AF1 compared to controls (data not shown), suggesting that downregulation of splicing and RRM genes is not common to all MDS samples but is instead associated with U2AF1 mutations. Mutations in U2AF1 are a previously unknown mechanism that could alter gene expression in MDS and expand the list of commonly mutated genes in MDS that may affect transcription or translation, including RPS14, TET2, EZH2, ASXL1 and DNMT3A (refs. [20] [21] [22] [23] [24] [25] [26] . Only two subjects in our cohort of 150 individuals with de novo MDS had a mutation in both DNMT3A and U2AF1 (Supplementary Table 7 ). Both of these mutations seem to be early genetic events in MDS, given their high mutant allele burdens in individuals with early stage disease 26 .
U2AF1 is highly conserved (Fig. 1a) 1 , and homozygous loss of U2AF1 is lethal in many organisms [27] [28] [29] . We did not observe any nonsense, frameshift or missense mutations affecting the coordinating CCCH residues in the zinc fingers, again suggesting the Ser34 alterations do not result in loss of function. The corresponding amino acid in the human ZFP36L2 protein (a ZFP36 family member) interacts with RNA through a hydrogen bond, further suggesting that the Ser34 position may be key for RNA binding 13 . Additionally, interactions between conserved aromatic amino acids in ZFP36 family members and the RNA bases stabilize the protein-RNA complexes formed 13 . The two amino acid substitutions we identified at Ser34 add a bulky aromatic ring (phenylalanine or tyrosine) to the zinc finger, which may alter, or even enhance, binding of the zinc finger to RNA. We suggest that the p.Ser34Phe and p.Ser34Tyr alterations in U2AF1 change the specificity of U2AF1-dependent splicing. Pre-mRNAs with strong polypyrimidine tracts can splice independently of U2AF1 in vitro, whereas weak polypyrimidine tracts are more dependent on U2AF1 for appropriate splicing 2, 11 . Therefore, the pattern of U2AF specificity (determined by both U2AF1 and U2AF2) may be influenced by the nucleotide sequence in pre-mRNAs and may be a key factor in determining which genes are altered in cells expressing mutant U2AF1. Alternative splicing has been described for a wide variety of cancers 30, 31 , although the underlying mechanisms that influence cancer pathogenesis are largely unknown. Alterations in the transcriptome that are mediated by alternative splicing may contribute directly to cancer or may contribute indirectly by engaging some other pathway. The identification of somatic mutations in spliceosome genes in MDS by our group and others [32] [33] [34] raises the possibility that mutations in splicing factors, including U2AF1, may be responsible for the observed alterations of splicing in cancer. Ultimately, cancer cells may generate diversity in a large number of genes by selecting cells with alterations in U2AF1 or other spliceosome proteins. Identification of key target genes affected by U2AF1 mutations will be crucial to our understanding of how these mutations contribute to MDS pathogenesis. In the absence of the Tra2α splicing enhancer or the hnRNPG splicing inhibitor, transient coexpression of mutated U2AF1 increases splicing of the pTN24 construct, resulting in an increase in the ratio of luciferase expression relative to β-galactosidase expression, compared to expression of wild-type U2AF1 (P < 0.001). Tra2α (positive control) and hnRNPG (negative control) cause increased or decreased splicing efficiency, respectively. A protein blot of U2AF1 using extracts from the same cells used for the luciferase assays is shown below each combination of plasmids. (b) Expression of the U2AF1 p.Ser34Phe mutant results in an increase in the splicing of the pTN24 construct and an increase in the luciferase expression compared to the control plasmid (P < 0.001). This result is independent of endogenous U2AF1 expression. A protein blot of U2AF1 using lysates from the same cells is shown below each condition. (c) The GH1 minigene was transiently transfected into 293T cells with a control plasmid, wild-type U2AF1 cDNA or mutant p.Ser34Phe U2AF1 cDNA in the presence of a control siRNA (siControl) or siRNA targeting endogenous U2AF1 (siU2AF1). RT-PCR using the indicated primers resulted in a fully spliced 505-bp amplicon or a 386-bp amplicon that skips the middle exon, which is shaded in black (exon skipping). A representative PCR gel image is shown, and the ratio of the lower band (amplicon b, representing exon skipping) relative to the normally spliced upper band (amplicon a) is shown above each condition. Expression of the U2AF1 p.Ser34Phe mutant results in an increase in exon skipping compared to expression of control or wild-type U2AF1 (P < 0.02). WT, wild type; Mut, mutant; T7, T7 primer. Error bars, s.d. l e t t e r s oNLINe MeTHoDS Flow sorting of bone marrow samples. Bone marrow cells from the sAML sample, cryopreserved in 10% DMSO, were rapidly thawed at 37 °C, washed and stained with PE-Cy7-conjugated hCD45, clone J.33 (Beckman Coulter), and fluorescein isothiocyanate (FITC)-conjugated anti-hCD34, clone 581 (Beckman Coulter). The blast population (cells with low side scatter and dim CD45 cell surface expression) was sorted using a reflection high-speed cell sorter (Sony iCyt) directly into lysis buffer, and genomic DNA was prepared by column purification (QIAGEN DNeasy).
WGS production. Four DNA libraries were generated for paired-end sequencing: two libraries from the tumor samples (flow-sorted sAML myeloblasts) and two libraries from the normal samples (punch biopsies of unaffected skin). Sequence data was generated using both Illumina GAIIx and Illumina HiSeq platforms in 2 × 100 paired-end reads. Reads were aligned individually to NCBI Build 36 of the human reference sequence using Burrows-Wheeler Aligner (BWA) 0.5.5 and SAMtools r544. Alignments were merged into a single BAM file and marked for duplicates using Picard 1.17 (see URLs). Only non-duplicate reads were used for the downstream analyses.
Somatic mutation detection. Candidate point mutations were predicted using SomaticSniper (data not shown), which was previously referred to as glfSomatic 4, 35 . Putative single SNVs with a somatic score of 40 and an average mapping quality of 40 were considered to be 'high confidence'; all other SNVs were deemed 'low confidence' . Small (<100 bp) insertion/deletion events (indels) were called using a combination of GATK 36 , IndelGenotyper, Pindel 37 and a modified version of SAMtools 38 . Both SNVs and indels were annotated using gene structure and conservation information and were classified by tier as previously described 4 . Briefly, tier 1 contains all changes in the amino acid coding regions of annotated exons, consensus splice-site regions and RNA genes (including microRNA genes). Tier 2 contains changes in highly conserved regions of the genome or regions that have regulatory potential. Tier 3 contains mutations in the nonrepetitive part of the genome that do not meet the tier 2 criteria. Tier 4 contains mutations in the remainder of the genome. High-confidence tier 2 and tier 3 mutations and all tier 1 mutations (regardless of confidence) were selected for validation (see below).
To identify somatic DNA copy number changes from the WGS data, reads aligned by BWA 39 were binned into contiguous, non-overlapping 1-kb windows. The copy number for each bin was normalized to the median copy number for each chromosome in the tumor and normal samples separately. A Hidden Markov Model algorithm 40 was used to generate a list of segments, and the copy number was expressed as log 2 (tumor copy number divided by normal copy number). Copy number changes were also probable if loss of heterozygosity was observed in the affected regions. In brief, heterozygous SNPs were identified in the WGS data from the normal sample (more than ten reads of over q10 quality with non-reference allele frequencies of 0.4-0.6). The variant allele frequencies at these positions were then averaged in bins of 20 consecutive SNPs and visualized for the normal and tumor samples separately. Deletions, amplifications and interchromosomal and intrachromsomal rearrangements were also predicted using the BreakDancer algorithm 41 .
Mutation validation.
To comprehensively evaluate predictions of tier 1-3 SNVs, we used a custom solid-phase capture platform. We selected all tier 1 SNV predictions (high confidence and low confidence) and all highconfidence tier 2 and 3 SNVs. Tier 1-3 indel predictions were also included. In addition, we used this approach to validate structural variants predictions (deletions and rearrangements). We identified at least eight SNPs that were heterozygous in the normal DNA sample (determined using the WGS and Affymetrix SNP array data) that were located within the affected segments and eight SNPs from flanking normal regions. The genomic positions of the SNVs and indels (with a 200-bp margin) and structural variants (with a 400-bp margin) were submitted for probe design. Probes were synthesized on custom HD2.1 long oligonucleotide arrays (Roche NimbleGen). Wholegenome-amplified DNA (REPLI-g, QIAGEN) from the normal (skin), unfractionated MDS and unfractionated sAML samples was used as bait for capture on the arrays, and the recovered DNA (enriched for target sequences) was resequenced on the Illumina GAIIx platform.
At least 10× coverage was obtained for ~87.16% of the target sequence for all samples (Supplementary Note and Supplementary Table 1 ). Reads were mapped using BWA 39 , deduplicated and merged into BAM files. The reference or somatic status at the nucleotide of interest was then determined for each sample using VarScan2 (ref. 42 ) with the following parameters: min-coverage = 10, min-var-freq = 0.05, somatic P value < 0.01 and validation = 1. To validate low-frequency (2-5%) SNVs, we reran VarScan with the following adjusted parameters: min-coverage = 100, min-var-freq = 0.02, somatic P value < 0.01 and validation = 1. In the validation mode, VarScan reads data from tumor and normal samples simultaneously, performing pairwise comparisons at each position that is covered in both samples. Each position is classified as 'reference' (wild type), 'germline' , 'LOH' (loss of heterozygosity) or 'somatic' based on a comparison of the consensus genotypes and the supporting read counts (Fisher's exact test). Positions called as somatic were further subjected to our internally developed false-positive filter, which removes sequencingand alignment-related artifacts using several criteria (read count, mapping quality, average read position, strand representation, homopolymer-like sequence context, mismatch quality sum difference, trimmed read length and Q2 distance), and were manually reviewed. Chromosome X and Y somatic positions were determined using the false-positive filter and manual review. SIFT and PolyPhen2 computational algorithms were used to predict whether U2AF1 mutations were damaging, as previously described 43, 44 .
Sanger sequencing. To screen for the recurrence of U2AF1 mutations, we performed Sanger sequencing using whole-genome-amplified DNA extracted from unfractionated bone marrow aspirates and paired normal tissue (skin) from 150 individuals with de novo MDS. PCR amplicons covering all nine exons and splice sites in U2AF1 were sequenced using BigDye chemistry and analyzed on an ABI 3730 sequencer (for the primer sequences used, see Supplementary Table 8 ). Sequence variants were called by The Genome Institute's mutational profiling pipeline and were manually reviewed. Potential somatic mutations (which were present in the bone marrow sample but were not detectable in skin) were confirmed by independent PCR and sequencing.
Deep sequencing of U2AF1 mutations in DNA and cDNA. Unfractionated bone marrow samples from 11 subjects with validated U2AF1 mutations were selected for deep sequencing to estimate clone size. Genomic DNA from normal (skin), MDS and sAML samples was amplified by PCR using barcoded primers (Supplementary Table 8 ). The products were then pooled and sequenced on the Roche 454 platform. In parallel, RNA was extracted from MDS and sAML samples (TRIzol, Invitrogen), converted to cDNA using the Ovation RNA-Seq Kit (NuGEN) and amplified with barcoded primers spanning the intron-exon boundaries ( Supplementary  Table 8 ). Reads were aligned to human reference sequence build 36 (NCBI) using BWA-Smith-Waterman alignment (BWA-SW) 39 . After alignment, BAM and pileup files were generated using SAMtools and analyzed using Picard to remove duplicates. Only uniquely mapped bases with quality scores over q20 were retained. Reads supporting the reference or variant allele were identified using VarScan2. SNP array analysis. Genomic DNA samples (which were not subjected to whole-genome amplification) from the normal, MDS and sAML specimens (which were not flow sorted) were hybridized to Affymetrix 6.0 SNP arrays (Affymetrix). An analysis of copy number alterations and copy-neutral loss of heterozygosity was performed using the Partek Genomics Suite (Partek). mRNA expression profiling. Total RNA was harvested from unfractionated bone marrow cells (69% myeloblast) from the sAML sample from subject UPN 266395 and hybridized to the Affymetrix Exon 1.0 ST array. Raw data were extracted using the Affymetrix Expression Console (Affymetrix) and analyzed in Prism 5.04 (GraphPad Software). Expression of tier 1 mutated genes for UPN 266395 was compared to the expression in 43 individuals with de novo AML ( Supplementary Table 9 ).
Total RNA was harvested from CD34 + purified MDS bone marrow samples (n = 15) and control bone marrow (n = 4) and hybridized to the Affymetrix U133 Plus 2 array, as previously reported 18 . Supervised hierarchical
